Ramesh Rengan

List of Publications by Citations

121 papers	4,464 citations	30 h-index	65 g-index
130 ext. papers	5,321 ext. citations	4.3 avg, IF	5.13 L-index

#	Paper	IF	Citations
121	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. *Nature*, **2015**, 520, 373-7	50.4	1509
120	Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. *International Journal of Radiation Oncology Biology Physics*, **2013**, 85, 444-50	4	384
119	Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. *International Journal of Radiation Oncology Biology Physics*, **2004**, 60, 741-7	4	131
118	Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer?. *International Journal of Radiation Oncology Biology Physics*, **2005**, 62, 70-5	4	125
117	Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. *International Journal of Radiation Oncology Biology Physics*, **2013**, 87, 690-6	4	120
116	Central-airway necrosis after stereotactic body-radiation therapy. *New England Journal of Medicine*, **2012**, 366, 2327-9	59.2	107
115	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. *Radiotherapy and Oncology*, **2020**, 146, 223-229	5.3	105
114	Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 505-516	4	99
113	Actin cytoskeletal function is spared, but apoptosis is increased, in WAS patient hematopoietic cells. *Blood*, **2000**, 95, 1283-1292	2.2	77
112	Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. *Molecular Pharmacology*, **2012**, 82, 1230-40	4.3	70
111	Stereotactic body radiation therapy for lung cancer. *Chest*, **2013**, 143, 1784-1790	5.3	68
110	Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2017**, 12, 281-292	8.9	66
109	Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes. *Radiotherapy and Oncology*, **2010**, 95, 178-84	5.3	66
108	Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. *Aids*, **2013**, 27, 459-68	3.5	65
107	A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response. *Journal of Thoracic Oncology*, **2012**, 7, 709-15	8.9	63
106	Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer. *Clinical Lung Cancer*, **2014**, 15, 79-85	4.9	56
105	Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study. *Clinical Lung Cancer*, **2015**, 16, 237-44	4.9	42

104	The use of proton therapy in the treatment of lung cancers. *Cancer Journal (Sudbury, Mass)*, **2014**, 20, 427-32	2.2	42
103	Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. *Lancet Oncology, The*, **2012**, 13, 1203-9	21.7	40
102	The role of radiation therapy in malignant thymoma: a Surveillance, Epidemiology, and End Results database analysis. *Journal of Thoracic Oncology*, **2010**, 5, 1454-60	8.9	40
101	Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection?. *Journal of Clinical Oncology*, **2005**, 23, 4905-12	2.2	39
100	Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer. *Cancer*, **2017**, 123, 4244-4251	6.4	37
99	Effect of body mass index on magnitude of setup errors in patients treated with adjuvant radiotherapy for endometrial cancer with daily image guidance. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, 670-5	4	37
98	Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy. *Medical Physics*, **2017**, 44, 3418-3429	4.4	36
97	Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. *Annals of Translational Medicine*, **2020**, 8, 482	3.2	35
96	An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer. *Radiation Oncology*, **2013**, 8, 144	4.2	34
95	Impact of PET staging in limited-stage small-cell lung cancer. *Journal of Thoracic Oncology*, **2013**, 8, 899-905	8.9	34
94	Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology Physics*, **2016**, 94, 612-20	4	32
93	Definitive radiotherapy for unresected adenoid cystic carcinoma of the trachea. *Chest*, **2012**, 141, 1323-1326	5.3	32
92	Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions. *Cancers*, **2015**, 7, 1178-90	6.6	30
91	Adjuvant radiotherapy for completely resected stage 2 thymoma. *Cancer*, **2011**, 117, 3502-8	6.4	30
90	Radiation injury to the normal brain measured by 3D-echo-planar spectroscopic imaging and diffusion tensor imaging: initial experience. *Journal of Neuroimaging*, **2015**, 25, 97-104	2.8	29
89	First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non-Small-Cell Lung Cancer. *Clinical Lung Cancer*, **2017**, 18, 364-371	4.9	28
88	Combination of stereotactic ablative body radiation with targeted therapies. *Lancet Oncology, The*, **2014**, 15, e426-34	21.7	28
87	Lessons Learned From Hurricane Maria in Puerto Rico: Practical Measures to Mitigate the Impact of a Catastrophic Natural Disaster on Radiation Oncology Patients. *Practical Radiation Oncology*, **2019**, 9, 305-321	2.8	26

86	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. *International Journal of Radiation Oncology Biology Physics*, **2020**, 107, 631-640	4	26
85	Advanced proton beam dosimetry part II: Monte Carlo pencil beam-based planning for lung cancer. *Translational Lung Cancer Research*, **2018**, 7, 114-121	4.4	24
84	Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications. *International Journal of Radiation Oncology Biology Physics*, **2013**, 85, 175-81	4	23
83	A moving target: Image guidance for stereotactic body radiation therapy for early-stage non-small cell lung cancer. *Practical Radiation Oncology*, **2013**, 3, 307-15	2.8	23
82	Dynamic simulation of motion effects in IMAT lung SBRT. *Radiation Oncology*, **2014**, 9, 225	4.2	23
81	High body mass index is associated with worse quality of life in breast cancer patients receiving radiotherapy. *Breast Cancer Research and Treatment*, **2013**, 141, 125-33	4.4	22
80	Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma. *Cancer Biology and Therapy*, **2010**, 10, 425-9	4.6	22
79	Framework for radiation pneumonitis risk stratification based on anatomic and perfused lung dosimetry. *Strahlentherapie Und Onkologie*, **2017**, 193, 410-418	4.3	21
78	Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies. *Practical Radiation Oncology*, **2019**, 9, 280-288	2.8	21
77	Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location. *Clinical Lung Cancer*, **2019**, 20, e63-e71	4.9	21
76	Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study. *Practical Radiation Oncology*, **2015**, 5, e355-63	2.8	18
75	Radiation Therapy in King County, Washington During the COVID-19 Pandemic: Balancing Patient Care, Transmission Mitigation, and Resident Training. *Advances in Radiation Oncology*, **2020**, 5, 544-547	3.3	18
74	Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial. *JAMA Oncology*, **2019**, 5, 1464-1472	13.4	18
73	Stereotactic body radiotherapy. *Seminars in Oncology*, **2014**, 41, 776-89	5.5	18
72	Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer. *Translational Lung Cancer Research*, **2018**, 7, 180-188	4.4	17
71	Integrating the healthcare enterprise in radiation oncology plug and play--the future of radiation oncology?. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, 333-6	4	16
70	Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation. *Translational Lung Cancer Research*, **2019**, 8, 5-14	4.4	16
69	New strategies in non-small cell lung cancer: improving outcomes in chemoradiotherapy for locally advanced disease. *Clinical Cancer Research*, **2011**, 17, 4192-9	12.9	15

68	Hemithoracic radiotherapy after extrapleural pneumonectomy for malignant pleural mesothelioma: a dosimetric comparison of two well-described techniques. *Journal of Thoracic Oncology*, **2009**, 4, 1431-7	8.9	15
67	Long-term neck control rates after complete response to chemoradiation in patients with advanced head and neck cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2008**, 31, 465-9	2.7	15
66	COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation. *Brachytherapy*, **2020**, 19, 401-411	2.4	15
65	Clinical target promiscuity: lessons from ras molecular trials. *Cancer and Metastasis Reviews*, **2008**, 27, 403-14	9.6	14
64	Ten-year results of preoperative radiation followed by sphincter preservation for rectal cancer: increased local failure rate in nonresponders. *Clinical Colorectal Cancer*, **2006**, 5, 413-21	3.8	14
63	Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis. *International Journal of Radiation Oncology Biology Physics*, **2015**, 91, 133-9	4	13
62	The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, 340-7	4	13
61	Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patients. *Cancer Biotherapy and Radiopharmaceuticals*, **2012**, 27, 412-9	3.9	13
60	Can we predict reactivity for aromatic nucleophilic substitution with [18F]fluoride ion?. *Journal of Labelled Compounds and Radiopharmaceuticals*, **1993**, 33, 563-572	1.9	12
59	Prognostic value of primary tumor FDG uptake for occult mediastinal lymph node involvement in clinically N2/N3 node-negative non-small cell lung cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2014**, 37, 135-9	2.7	11
58	Correlation of Functional Lung Heterogeneity and Dosimetry to Radiation Pneumonitis using Perfusion SPECT/CT and FDG PET/CT Imaging. *International Journal of Radiation Oncology Biology Physics*, **2018**, 102, 1255-1264	4	10
57	The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients. *Advances in Radiation Oncology*, **2017**, 2, 192-196	3.3	9
56	International outreach: what is the responsibility of ASTRO and the major international radiation oncology societies?. *International Journal of Radiation Oncology Biology Physics*, **2014**, 89, 481-4	4	9
55	Phase I randomized double-blind placebo-controlled single-dose safety studies of Bowman-Birk inhibitor concentrate. *Oncology Letters*, **2014**, 7, 1151-1158	2.6	9
54	Does Neutron Radiation Therapy Potentiate an Immune Response to Merkel Cell Carcinoma?. *International Journal of Particle Therapy*, **2018**, 5, 183-195	1.5	9
53	Oligometastatic non-small-cell lung cancer: current treatment strategies. *Lung Cancer: Targets and Therapy*, **2016**, 7, 129-140	2.9	9
52	A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. *OncoImmunology*, **2021**, 10, 1863631	7.2	9
51	Rectal Hydrogel Spacer Improves Late Gastrointestinal Toxicity Compared to Rectal Balloon Immobilization After Proton Beam Radiation Therapy for Localized Prostate Cancer: A Retrospective Observational Study. *International Journal of Radiation Oncology Biology Physics*, **2020**, 108, 635-643	4	8

50	New approaches to radiotherapy as definitive treatment for inoperable lung cancer. *Seminars in Thoracic and Cardiovascular Surgery*, **2008**, 20, 188-97	1.7	8
49	Regulation of oscillations in filamentous actin content in polymorphonuclear leukocytes stimulated with leukotriene B(4) and platelet-activating factor. *Biochemical and Biophysical Research Communications*, **1999**, 262, 479-86	3.4	8
48	Proton Therapy for Malignant Pleural Mesothelioma: A Three Case Series Describing the Clinical and Dosimetric Advantages of Proton-Based Therapy. *Cureus*, **2017**, 9, e1705	1.2	8
47	Voxel Forecast for Precision Oncology: Predicting Spatially Variant and Multiscale Cancer Therapy Response on Longitudinal Quantitative Molecular Imaging. *Clinical Cancer Research*, **2019**, 25, 5027-5037	12.9	7
46	Ill-posed problem and regularization in reconstruction of radiobiological parameters from serial tumor imaging data. *Physics in Medicine and Biology*, **2015**, 60, 8491-503	3.8	7
45	ACR-ASTRO Practice Parameter for the Performance of Stereotactic Body Radiation Therapy. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2020**, 43, 545-552	2.7	7
44	Comparison of regional lung perfusion response on longitudinal MAA SPECT/CT in lung cancer patients treated with and without functional tissue-avoidance radiation therapy. *British Journal of Radiology*, **2019**, 92, 20190174	3.4	6
43	A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology Physics*, **2020**, 108, 170-177	4	6
42	Decision analytic modeling for the economic analysis of proton radiotherapy for non-small cell lung cancer. *Translational Lung Cancer Research*, **2018**, 7, 122-133	4.4	6
41	Prospective assessment of demographic characteristics associated with worse health related quality of life measures following definitive chemoradiation in patients with locally advanced non-small cell lung cancer. *Translational Lung Cancer Research*, **2019**, 8, 332-339	4.4	5
40	Addressing connectivity issues: The Integrating the Healthcare Enterprise-Radiation Oncology (IHE-RO) initiative. *Practical Radiation Oncology*, **2011**, 1, 226-31	2.8	5
39	Adjuvant cisplatin and docetaxel for non-small cell lung cancer: the Hospital of the University of Pennsylvania experience. *Journal of Thoracic Oncology*, **2010**, 5, 667-72	8.9	5
38	Sensitivity analysis of FDG PET tumor voxel cluster radiomics and dosimetry for predicting mid-chemoradiation regional response of locally advanced lung cancer. *Physics in Medicine and Biology*, **2020**, 65, 205007	3.8	4
37	Consensus Statement on Proton Therapy in Mesothelioma. *Practical Radiation Oncology*, **2021**, 11, 119-133	2.8	4
36	Challenge of Proving the Value of Proton Therapy in an Unselected Patient Population in the Era of Precision Oncology: The Fallacy of a One-Size-Fits-All Strategy in Radiotherapy for Lung Cancer. *Journal of Clinical Oncology*, **2018**, 36, 2003-2004	2.2	4
35	Education and Training Needs in Radiation Oncology in India: Opportunities for Indo-US Collaborations. *International Journal of Radiation Oncology Biology Physics*, **2015**, 93, 957-60	4	3
34	Scanning Beam Proton Therapy versus Photon IMRT for Stage III Lung Cancer: Comparison of Dosimetry, Toxicity, and Outcomes. *Advances in Radiation Oncology*, **2020**, 5, 434-443	3.3	3
33	The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer. *Clinical Lung Cancer*, **2018**, 19, e205-e209	4.9	3

32	Impact of sociodemographic factors on the radiotherapeutic management of lung cancer: Results of a Quality Research in Radiation Oncology survey. *Practical Radiation Oncology*, **2014**, 4, e167-e179	2.8	3
31	The Practicality of ICRU and Considerations for Future ICRU Definitions. *Seminars in Radiation Oncology*, **2018**, 28, 201-206	5.5	3
30	Radiation and Modulation of the Tumor Immune Microenvironment in Non-Small Cell Lung Cancer. *Seminars in Radiation Oncology*, **2021**, 31, 133-139	5.5	3
29	Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience. *Advances in Radiation Oncology*, **2019**, 4, 70-78	3.3	3
28	Dose Escalation Optimization in Patients With Locally Advanced Non-Small-Cell Lung Cancer: The Right Dose, in the Right Location, to the Right Patient, at the Right Time. *JAMA Oncology*, **2017**, 3, 1365-1367	13.4	2
27	4D computed tomography scans for conformal thoracic treatment planning: is a single scan sufficient to capture thoracic tumor motion?. *Physics in Medicine and Biology*, **2018**, 63, 02NT03	3.8	2
26	Role of particle beam therapy in a trimodality approach to locally advanced non-small cell lung cancer. *Thoracic Cancer*, **2013**, 4, 95-101	3.2	2
25	A glimpse of the future: where will new combinations of diagnostics and therapies take us?. *Cancer Journal (Sudbury, Mass)*, **2011**, 17, 190-4	2.2	2
24	Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. *Translational Lung Cancer Research*, **2017**, 6, 169-177	4.4	2
23	Volume effects in the TCP for hypoxic and oxygenated tumors. *Medical Physics*, **2020**, 47, 4626-4633	4.4	1
22	Intratumoral G100 Rescues Radiation-Induced T Cell Depletion and Has Synergistic Anti-Tumor Effect with Local Irradiation in A20 Lymphoma. *Blood*, **2016**, 128, 4166-4166	2.2	1
21	Multi-institutional study of reirradiation with proton beam radiotherapy for non-small cell lung cancer.. *Journal of Clinical Oncology*, **2013**, 31, 7578-7578	2.2	1
20	Uncommon Thoracic Tumors **2012**, 859-889		1
19	Dietary Flaxseed in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation. *Journal of Pulmonary & Respiratory Medicine*, **2013**, 3, 154	0	1
18	Reliability of Quantitative 18F-FDG PET/CT Imaging Biomarkers for Classifying Early Response to Chemoradiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer. *Clinical Nuclear Medicine*, **2021**, 46, 861-871	1.7	1
17	Corneal Substructure Dosimetry Predicts Corneal Toxicity in Patients With Uveal Melanoma Treated With Proton Beam Therapy. *International Journal of Radiation Oncology Biology Physics*, **2019**, 104, 374-382	4	0
16	Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes. *Radiation Oncology*, **2018**, 13, 179	4.2	0
15	Treatment of ocular tumors through a novel applicator on a conventional proton pencil beam scanning beamline.. *Scientific Reports*, **2022**, 12, 4648	4.9	0

14	Implementation of patient reported outcomes in definitive chemoradiation for non-small cell lung cancer. *Translational Lung Cancer Research*, **2020**, 9, 154-155	4.4
13	Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer.. *Advances in Radiation Oncology*, **2022**, 7, 100857	3.3
12	Long-term results of a phase I/II trial of nelfinavir with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.. *Journal of Clinical Oncology*, **2018**, 36, 8552-8552	2.2
11	Prognostic role of mid-treatment PET/CT and plasma cytokines in patients undergoing chemoradiation for locally advanced non-small cell lung cancer (LA-NSCLC).. *Journal of Clinical Oncology*, **2020**, 38, 9040-9040	2.2
10	Actionable policy barriers for receiving standard of care treatment among unresected stage III non-small cell lung cancer (NSCLC) patients in the United States.. *Journal of Clinical Oncology*, **2020**, 38, 2069-2069	2.2
9	Concurrent and sequential chemoradiation therapy are associated with improved survival among unresected stage III non-small cell lung cancer patients in the United States.. *Journal of Clinical Oncology*, **2020**, 38, 7043-7043	2.2
8	Definitive thoracic radiotherapy in oligometastatic stage IV non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2012**, 30, e18032-e18032	2.2
7	Disparities in the treatment and outcomes of lung cancer among HIV-infected people in Texas.. *Journal of Clinical Oncology*, **2012**, 30, 6070-6070	2.2
6	Impact of PET staging in limited-stage SCLC.. *Journal of Clinical Oncology*, **2012**, 30, 7098-7098	2.2
5	A strategy to reduce acute toxicity from chemoradiation therapy for limited-stage small cell lung cancer.. *Journal of Clinical Oncology*, **2012**, 30, e17534-e17534	2.2
4	Case-control study of prophylactic cranial irradiation in nonmetastatic non-small cell lung cancer.. *Journal of Clinical Oncology*, **2012**, 30, 7050-7050	2.2
3	Phase II Trial of Flaxseed to Prevent Acute Complications After Chemoradiation for Lung Cancer. *Journal of Alternative and Complementary Medicine*, **2021**, 27, 824-831	2.4
2	Uncommon Thoracic Tumors **2016**, 865-894.e8	
1	Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry.. *Advances in Radiation Oncology*, **2022**, 7, 100767	3.3